Our new paper was just published in the special edition of New Biotechnology. This is a review with the title: “The triad of success in personalised medicine: pharmacogenomics, biotechnology and regulatory issues from a Central European perspective“. An excerpt from the abstract:
We also present the state of the biotechnology market from a European perspective, discuss how spin-offs leverage the power of genomic technologies and describe how they might contribute to personalised medicine.
As ethical, legal and social issues are essential in the area of genomics, we analysed these aspects and present here the European situation with a special focus on Hungary.
We propose that the synergy of these three issues: pharmacogenomics, biotechnology and regulatory issues should be considered a triad necessary to succeed in personalised medicine.